Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab in advanced lung cancer
ChiCTR2000034595Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in bronchial carcinoma, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Progression-free survival. Started Aug 2019; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2000034595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034595.